Current Affairs Topics Archive
International Relations Economics Polity & Governance Environment & Ecology Science & Technology Internal Security Geography Social Issues Art & Culture Modern History

Gender and identity: New questions arise

April 01, 2026 5 min read Social Issues Science & Technology Polity & Governance GS2 GS3
On This Page ▼

What Happened

  • The Transgender Persons (Protection of Rights) Amendment Act, 2026 received Presidential assent after being passed by Parliament on March 25, 2026 — sparking major controversy and protests from the transgender community and rights groups.
  • The Amendment Bill, introduced in Lok Sabha on March 13, 2026, fundamentally restricts the definition of a transgender person from an inclusive self-identification framework to three narrow categories: (i) socio-cultural identities (hijra, kinner, aravani, jogta, eunuch); (ii) persons with specific intersex variations; and (iii) those "compelled" to present as transgender.
  • The bill removes the right to self-perceived gender identity enshrined in the 2019 Act, effectively eliminating legal recognition for trans men, trans women, and gender non-binary people outside these three categories.
  • A medical board certification process (headed by Chief Medical Officer/Deputy CMO) will now be required for identity certificates, replacing the earlier self-identification model.
  • Human Rights Watch has called it "a huge setback," noting it conflicts with the Supreme Court's 2014 NALSA judgment that recognised self-identification as a constitutional right.
  • Separately: courts in at least one jurisdiction have issued verdicts on social media platform liability for addictive design features harming minors; GLP-1 (glucagon-like peptide-1) receptor agonist weight loss drugs continue expanding into new clinical applications; and a new Covid-19 subvariant is under WHO monitoring.

Static Topic Bridges

The NALSA Judgment (2014) and Transgender Constitutional Rights

On April 15, 2014, the Supreme Court of India delivered a landmark judgment in National Legal Services Authority v. Union of India (NALSA judgment) — the foundational constitutional ruling on transgender rights in India. The Court, invoking Articles 14 (equality), 15–16 (non-discrimination), 21 (right to life with dignity), and 19(1)(a) (freedom of expression), affirmed that gender identity is central to personal dignity and autonomy. It declared that every person has the right to self-identify their gender as male, female, or third gender, without requiring surgery or medical certification.

  • The NALSA judgment explicitly declared sex reassignment surgery (SRS) as a precondition for gender recognition to be illegal.
  • The Court directed the Central and State governments to legally recognise "third gender" across all official documents.
  • It directed that transgender persons be treated as a "socially and educationally backward class" entitled to reservations in education and public employment.
  • The judgment grounded gender identity in the fundamental right to dignity under Article 21 — a non-derogable right.
  • The 2019 Transgender Persons Act partially implemented NALSA but retained a medical board certificate requirement — already criticised as NALSA-inconsistent.

Connection to this news: The 2026 Amendment further deepens the departure from NALSA by narrowing the definition to exclude self-identified trans men and women — critics argue this is directly unconstitutional under the NALSA framework and will face a Supreme Court challenge.

The Transgender Persons (Protection of Rights) Act, 2019: Original Framework

The Transgender Persons (Protection of Rights) Act, 2019 was India's first comprehensive legislation specifically protecting transgender rights. It defined "transgender person" broadly (including intersex variations, socio-cultural identities, and gender non-conforming identities), prohibited discrimination in education, employment, healthcare, and public services, and required a certificate of identity issued by a District Magistrate (with a screening committee, which was later struck down as unconstitutional by the Madras HC). The Act established the National Council for Transgender Persons.

  • The 2019 Act provided for welfare measures including social security, healthcare, and rehabilitation.
  • Section 18 created penal provisions for offences like begging, bonded labour, and abuse of transgender persons (penalties criticised as weak — max 2 years).
  • The 2026 Amendment significantly strengthens criminal penalties: kidnapping/grievous hurt to force transgender identity — 10 years to life (adult victim), life imprisonment (minor victim).
  • The 2026 Amendment's definitional restriction is the key controversy — not the strengthened penalties.

Connection to this news: The 2026 Amendment modifies the 2019 Act in a direction critics call regressive on rights (narrower definition) while strengthening criminal law protections — a contradictory mix that reflects competing political pressures around the bill.

GLP-1 Receptor Agonists: Science and Policy Implications

Glucagon-like peptide-1 (GLP-1) receptor agonists are a class of drugs originally developed for type-2 diabetes management (e.g., semaglutide — brand names Ozempic and Wegovy; liraglutide — Victoza and Saxenda). They work by mimicking the GLP-1 hormone, which stimulates insulin secretion, suppresses glucagon, slows gastric emptying, and reduces appetite. Their dramatic weight loss effects have made them a transformative category in obesity medicine, with clinical trials showing 15–20% bodyweight reduction. Emerging research is exploring applications in cardiovascular disease, addiction (alcohol, nicotine), neurological conditions (Alzheimer's), and even cancer risk reduction.

  • Semaglutide (Ozempic/Wegovy): approved by the US FDA for diabetes (2017), obesity (2021); weekly subcutaneous injection.
  • Tirzepatide (Mounjaro/Zepbound): dual GLP-1/GIP agonist, approved for obesity 2023; shows even higher weight loss (~22% in trials).
  • Access and affordability are major concerns — Wegovy costs ~$1,300/month in the US without insurance.
  • India-based generic manufacturers are developing biosimilar versions, creating a potential access opportunity.
  • Regulatory framework: GLP-1 drugs are prescription-only; Central Drugs Standard Control Organisation (CDSCO) approves in India.

Connection to this news: The expanding clinical frontier of GLP-1 drugs raises important questions for India's pharmaceutical policy, healthcare access, and CDSCO regulatory capacity — a topic increasingly relevant for GS3 (biotechnology, pharma policy) and GS2 (healthcare governance).

Key Facts & Data

  • Transgender Persons Amendment Bill introduced in Lok Sabha: March 13, 2026
  • Passed by Parliament (Lok Sabha + Rajya Sabha): March 25, 2026; Presidential assent: shortly after
  • NALSA judgment: April 15, 2014 (Supreme Court, 2-judge bench — Justices K S Radhakrishnan and A K Sikri)
  • Transgender Persons (Protection of Rights) Act, 2019: Original legislation being amended
  • 2026 Amendment: removes self-identification right, narrows definition to 3 categories, requires medical board certificate
  • New penal provisions: 10 years to life (adult victim), life imprisonment (child victim) for coerced identity crimes
  • GLP-1 drug semaglutide: 15–20% weight loss in clinical trials; approved by FDA for obesity (2021)
  • GLP-1 drug tirzepatide: ~22% weight loss; dual GLP-1/GIP agonist
  • CDSCO: India's drug regulator (under Ministry of Health and Family Welfare)
  • Constitution — Articles 14, 15, 16, 19(1)(a), 21: basis of NALSA judgment on transgender rights